Healthcare / BiotechnologyTSXV
$0.04
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-3.4M · quality 65.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6M
P/E
N/A
•EV/EBITDA
N/A
•ROE
364.5%
↑Gross Margin
-0.1%
↓Debt/Equity
-3.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+39.8%
FCF CAGR
—
FCF margin
-787.3%
FCF / Net income
1.24x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $427869.0 · net income $-2.7M · FCF $-3.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $427869.00 | $427869.00 | $2.1M | $148980.00 | $156733.00 |
| Net Income | $-2.7M | $-2.7M | $6.1M | $-5.0M | $-3.9M |
| EBITDA | $-2.4M | $-2.4M | $-3.7M | $-3.1M | $-2.9M |
| EPS | — | — | 0.04 | -0.04 | -0.03 |
| Gross Margin | -0.1% | -0.1% | 41.9% | 73.5% | 71.5% |
| Operating Margin | -620.2% | -620.2% | -188.5% | -2253.6% | -2206.0% |
| Net Margin | -636.0% | -636.0% | 293.0% | -3379.0% | -2481.9% |
| Balance Sheet | |||||
| Debt/Equity | -3.09 | -3.09 | -1.34 | -0.88 | -1.05 |
| Current Ratio | 0.45 | 0.45 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.4M | $-3.4M | $-4.2M | $-2.1M | $-3.1M |
| Returns | |||||
| ROE | 364.5% | 364.5% | -374.3% | 47.7% | 59.6% |
| Valuation | |||||
| P/E | — | — | 2.75 | — | — |
| Growth & Yield | |||||
| Revenue Growth | -79.4% | -79.4% | 1296.8% | -4.9% | — |
| EPS Growth | — | — | 200.0% | -33.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.04 → n/d
Residual
-33.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.